Book:Bc3sigtrann

Global Tyrosine Protein Kinase Mer Pipeline Overview 2020 with Analysis by Indication, Stage of Development, Mechanism of Action, Route of Administration and Molecule Type

Retrieved on: 
Thursday, March 26, 2020

DUBLIN, March 26, 2020 /PRNewswire/ -- The "Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 26, 2020 /PRNewswire/ -- The "Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules.
  • This report outlays comprehensive information on the Tyrosine Protein Kinase Mer targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Tyrosine Protein Kinase Mer targeted therapeutics development with respective active and dormant or discontinued projects.

Mitogen Activated Protein Kinase 1, Pipeline Review, H2 2019 - Antengene Corp, Kura Oncology Inc & Kalyra Pharmaceuticals Inc - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020

The "Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019" drug pipelines have been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019" drug pipelines have been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019', Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) pipeline Target constitutes close to 14 molecules.
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Mitogen-activated protein kinase 1 is an enzyme encoded by the MAPK1 gene.
  • The report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020

The "RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules.
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene.
  • The report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.